TY  - JOUR
AU  - Quiñonero, Francisco
AU  - Mesas, Cristina
AU  - Muñoz-Gamez, Jose A
AU  - Jimenez-Luna, Cristina
AU  - Perazzoli, Gloria
AU  - Prados, Jose
AU  - Melguizo, Consolacion
AU  - Ortiz, Raul
PY  - 2022
DO  - 10.1016/j.biopha.2022.113669
UR  - http://hdl.handle.net/10668/22049
T2  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
AB  - Pancreatic cancer (PC) is one of the tumors with the lowest survival rates due to the poor efficacy of the treatments currently used. Gemcitabine (GMZ), one of the chemotherapeutic agents employed when the tumor is unresectable, frequently fails due...
LA  - en
PB  - Elsevier Masson
KW  - Drug resistance
KW  - Gemcitabine
KW  - Olaparib
KW  - PARP1
KW  - Pancreatic cancer
KW  - Humans
KW  - Xenograft Model Antitumor Assays
KW  - Cell Line, Tumor
KW  - Poly (ADP-Ribose) Polymerase-1
KW  - Pancreatic Neoplasms
KW  - Antineoplastic Agents
KW  - Gemcitabine
TI  - PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine.
TY  - research article
VL  - 155
ER  -